Piotr L. Rutkowski
Expertise in
28
conditions

Piotr L. Rutkowski

Cracow Branch, 
Krakow, MA, PL 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
28
conditions
Cracow Branch, 
Krakow, MA, PL 

Overview

Piotr Rutkowski practices practicing medicine in Krakow, Poland.

Mr. Rutkowski is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Melanoma, Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Lymphadenectomy, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 552 peer reviewed articles and participating in 12 clinical trials.

Gender

Male

Locations

Cracow Branch, Krakow, MA, Poland
Other Locations
Gliwice Branch, Gliwice, SL, Poland
Cracow Branch, Krakow, MA 31115, Poland
W. K. Roentgena 5 Street, Warsaw, MZ 02781, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Enrollment Status: Recruiting
Publish Date: June 24, 2026
Intervention Type: Genetic
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Completed
Publish Date: March 17, 2026
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
Combination of Targeted Therapy (Encorafenib and Binimetinib) Followed by Combination of Immunotherapy (Ipilimumab and Nivolumab) vs Immediate Combination of Immunotherapy in Patients With Unresectable or Metastatic Melanoma With BRAF V600 Mutation : an EORTC Randomized Phase II Study (EBIN)
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Drug
Study Drugs: Nivolumab + Ipilimumab, Encorafenib + Binimetinib
Study Phase: Phase 2
Hyperthermia and Radiotherapy in the Treatment for In-field Recurrent and Radiation-induced Soft Tissue and Bone Sarcomas
Hyperthermia and Radiotherapy in the Treatment for In-field Recurrent and Radiation-induced Soft Tissue and Bone Sarcomas
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Radiation, Other
Study Phase: Not Applicable
A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: January 27, 2025
Intervention Type: Biological, Drug
Study Drugs: Cemiplimab, RP1
Study Phase: Phase 2
Minitub: Prospective Registry of Sentinel Node (SN) Positive Melanoma Patients With Minimal SN Tumor Burden Who Undergo Completion Lymph Node Dissection (CLND) or Nodal Observation
Minitub: Prospective Registry of Sentinel Node (SN) Positive Melanoma Patients With Minimal SN Tumor Burden Who Undergo Completion Lymph Node Dissection (CLND) or Nodal Observation
Enrollment Status: Active_not_recruiting
Publish Date: November 28, 2023
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of Cabiralizumab, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT)
A Phase 1/2 Study of Cabiralizumab, an Anti-CSF1 Receptor Antibody, in Patients With Pigmented Villonodular Synovitis (PVNS)/ Diffuse Type Tenosynovial Giant Cell Tumor (Dt-TGCT)
Enrollment Status: Completed
Publish Date: August 31, 2021
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas
Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas
Enrollment Status: Unknown
Publish Date: February 01, 2021
Intervention Type: Radiation, Other
Study Phase: Phase 2
View 9 Less Clinical Trials

552 Total Publications

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.
COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 12, 2026

Frequently Asked Questions about Piotr L. Rutkowski

Is Piotr L. Rutkowski a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Piotr L. Rutkowski is classified as an Elite expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Piotr L. Rutkowski participate in research or clinical trials?

Yes. Piotr L. Rutkowski has published 552 articles and abstracts on conditions like Melanoma. You can view a list of Piotr L. Rutkowski's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Rutkowski's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 15 Advanced Conditions
View All 45 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile